Anatomy-Driven Model Aims to Prevent GLP-1 RA–Associated Facial Aging
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may be associated with rapid, region-specific facial volume loss, prompting researchers to propose an anatomy-driven framework for identifying patients at risk and intervening before visible facial aging progresses.
In a recent article published in Aesthetic Plastic Surgery, Castrellon and colleagues introduced a risk-stratification model and 4-phase prevention algorithm designed to shift management of GLP-1 RA–associated facial changes from late-stage correction toward earlier intervention.
According to the authors, existing literature on the phenomenon commonly called “Ozempic face” remains primarily descriptive and focused on correcting changes after they occur. Their proposed framework instead integrates facial aging biomechanics, emerging literature on GLP-1 RA–associated changes, and clinical pattern recognition to identify anatomical phenotypes that may be more susceptible to facial aging during weight loss.
The model stratifies risk according to anatomical phenotype and pairs that assessment with a 4-phase conceptual prevention algorithm aligned with the kinetics of weight loss. The framework also incorporates patient-specific modifiers, early intervention strategies, and clinical “off-ramps” intended to help clinicians individualize management as facial changes develop.
The authors described the approach as “a shift from reactive correction to preventive, anatomy-based management of [GLP-1 RA–associated] facial changes.”
For dermatologists and other clinicians providing aesthetic care, the proposed framework highlights the potential value of assessing facial anatomy and anticipated weight-loss patterns before significant volume changes occur. Such assessment could support earlier discussions with patients receiving GLP-1 RAs about possible aesthetic changes and facilitate individualized monitoring throughout weight loss.
The authors emphasized that “future studies are needed to validate and refine this framework.” Prospective research will therefore be necessary to determine whether anatomy-based risk stratification and preventive intervention can reliably reduce or modify GLP-1 RA–associated facial aging.
Reference
Castrellon R, Maita K, Witt E, Young V, Torres-Guzman, Huaman G. Preventing GLP-1-associated facial aging: an anatomy-driven risk stratification model and prevention algorithm in the "Ozempic face" era. Aesthetic Plast Surg. 2026;50(15):6226-6229. doi: 10.1007/s00266-026-05953-6
